ABIVAX press release
Abivax announces the resumption of trading of its ordinary shares on Euronext Paris.
Abivax SA (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on the development of therapeutic treatments that exploit the body’s natural regulatory mechanisms to modulate the immune response in patients suffering from inflammatory diseases chronicles, announces the resumption of trading of its ordinary shares on Euronext in Paris (“Euronext Paris”) from 4:20 p.m. (CEST).